Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




New Practice Guidelines Recommends Screening Couples for SMA

By LabMedica International staff writers
Posted on 15 Dec 2008
Spinal muscular atrophy (SMA) is a severe neuromuscular disease caused by mutations in the survival of motor neuron 1 (SMN1) gene. More...
New guidelines recommend that screening for carriers of the mutations in the recessive SMA gene should be made available for all couples.

An accurate genetic test is available for detecting the SMN1 gene mutation that causes SMA. In the past, these tests were mainly offered to families with a child affected by SMA; individuals without a history of the disorder were not tested. The only way to identify couples at high risk of carrying the abnormal SMN1 genes is by DNA testing.

Mutations in the SMN1 gene cause degeneration of motor neurons in the spinal cord, leading to progressive muscle weakness and paralysis. Children with the most common and severe type of SMA (type I, also called Werdnig-Hoffman syndrome) have severe, generalized muscle weakness, usually leading to death from respiratory failure before age two. Other types of SMA are less severe, but are also serious and disabling.

The new practice guideline was issued by the American College of Medical Genetics (ACMG). A statement in the November 2008 issue of Genetics in Medicine, the official journal of the ACMG, recommends, "Because SMA is a common genetic disorder in all populations, carrier testing should be offered to all couples regardless of race or ethnicity." The statement was authored by Thomas W. Prior, Ph.D., professor at Ohio State University (Columbus, Ohio, USA).

SMA testing is to be voluntary and formal genetic counseling will be made available to everyone requesting the testing.

Related Links:
American College of Medical Genetics
Ohio State University


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.